Literature DB >> 17449559

Gene-environment interactions in parkinsonism and Parkinson's disease: the Geoparkinson study.

F D Dick1, G De Palma, A Ahmadi, A Osborne, N W Scott, G J Prescott, J Bennett, S Semple, S Dick, P Mozzoni, N Haites, S Bezzina Wettinger, A Mutti, M Otelea, A Seaton, P Soderkvist, A Felice.   

Abstract

OBJECTIVES: To investigate associations of Parkinson's disease (PD) and parkinsonian syndromes with polymorphic genes that influence metabolism of either foreign chemical substances or dopamine and to seek evidence of gene-environment interaction effects that modify risk.
METHODS: A case-control study of 959 prevalent cases of parkinsonism (767 with PD) and 1989 controls across five European centres. Occupational hygienists estimated the average annual intensity of exposure to solvents, pesticides and metals, (iron, copper, manganese), blind to disease status. CYP2D6, PON1, GSTM1, GSTT1, GSTM3, GSTP1, NQO1, CYP1B1, MAO-A, MAO-B, SOD 2, EPHX, DAT1, DRD2 and NAT2 were genotyped. Results were analysed using multiple logistic regression adjusting for key confounders.
RESULTS: There was a modest but significant association between MAO-A polymorphism in males and disease risk (G vs T, OR 1.30, 95% CI 1.02 to 1.66, adjusted). The majority of gene-environment analyses did not show significant interaction effects. There were possible interaction effects between GSTM1 null genotype and solvent exposure (which were stronger when limited to PD cases only).
CONCLUSIONS: Many small studies have reported associations between genetic polymorphisms and PD. Fewer have examined gene-environment interactions. This large study was sufficiently powered to examine these aspects. GSTM1 null subjects heavily exposed to solvents appear to be at increased risk of PD. There was insufficient evidence that the other gene-environment combinations investigated modified disease risk, suggesting they contribute little to the burden of PD.

Entities:  

Mesh:

Year:  2007        PMID: 17449559      PMCID: PMC2078383          DOI: 10.1136/oem.2006.032078

Source DB:  PubMed          Journal:  Occup Environ Med        ISSN: 1351-0711            Impact factor:   4.402


  26 in total

1.  Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease.

Authors:  C A Smith; A C Gough; P N Leigh; B A Summers; A E Harding; D M Maraganore; S G Sturman; A H Schapira; A C Williams; D M Maranganore
Journal:  Lancet       Date:  1992-06-06       Impact factor: 79.321

2.  A sequencing method based on real-time pyrophosphate.

Authors:  M Ronaghi; M Uhlén; P Nyrén
Journal:  Science       Date:  1998-07-17       Impact factor: 47.728

3.  Glutathione S-transferase M1 null genotype as a risk modifier for solvent-induced chronic toxic encephalopathy.

Authors:  P Söderkvist; A Ahmadi; A Akerbäck; O Axelson; U Flodin
Journal:  Scand J Work Environ Health       Date:  1996-10       Impact factor: 5.024

4.  A multiplex polymerase chain reaction protocol for the simultaneous analysis of the glutathione S-transferase GSTM1 and GSTT1 polymorphisms.

Authors:  M Arand; R Mühlbauer; J Hengstler; E Jäger; J Fuchs; L Winkler; F Oesch
Journal:  Anal Biochem       Date:  1996-04-05       Impact factor: 3.365

5.  PCR detection of the TaqA RFLP at the DRD2 locus.

Authors:  D K Grandy; Y Zhang; O Civelli
Journal:  Hum Mol Genet       Date:  1993-12       Impact factor: 6.150

6.  Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema.

Authors:  C A Smith; D J Harrison
Journal:  Lancet       Date:  1997-08-30       Impact factor: 79.321

7.  Human monoamine oxidase A gene determines levels of enzyme activity.

Authors:  G S Hotamisligil; X O Breakefield
Journal:  Am J Hum Genet       Date:  1991-08       Impact factor: 11.025

8.  Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer.

Authors:  J M Lancaster; H A Brownlee; D A Bell; P A Futreal; J R Marks; A Berchuck; R W Wiseman; J A Taylor
Journal:  Mol Carcinog       Date:  1996-11       Impact factor: 4.784

9.  Evolution of haplotypes at the DRD2 locus.

Authors:  C M Castiglione; A S Deinard; W C Speed; G Sirugo; H C Rosenbaum; Y Zhang; D K Grandy; E L Grigorenko; B Bonne-Tamir; A J Pakstis
Journal:  Am J Hum Genet       Date:  1995-12       Impact factor: 11.025

10.  Combined effect of polymorphic GST genes on individual susceptibility to lung cancer.

Authors:  S T Saarikoski; A Voho; M Reinikainen; S Anttila; A Karjalainen; C Malaveille; H Vainio; K Husgafvel-Pursiainen; A Hirvonen
Journal:  Int J Cancer       Date:  1998-08-12       Impact factor: 7.396

View more
  46 in total

Review 1.  Pharmacogenetics of antidepressant response.

Authors:  Stefano Porcelli; Antonio Drago; Chiara Fabbri; Sara Gibiino; Raffaella Calati; Alessandro Serretti
Journal:  J Psychiatry Neurosci       Date:  2011-03       Impact factor: 6.186

2.  Association of Parkinson disease age of onset with DRD2, DRD3 and GRIN2B polymorphisms.

Authors:  Anhar Hassan; Michael G Heckman; J E Ahlskog; Zbigniew K Wszolek; Daniel J Serie; Ryan J Uitti; Jay A van Gerpen; Michael S Okun; Sruti Rayaprolu; Owen A Ross
Journal:  Parkinsonism Relat Disord       Date:  2015-11-25       Impact factor: 4.891

Review 3.  Genetics of iron regulation and the possible role of iron in Parkinson's disease.

Authors:  Shannon L Rhodes; Beate Ritz
Journal:  Neurobiol Dis       Date:  2008-07-11       Impact factor: 5.996

4.  No evidence for association between an MAOA functional polymorphism and susceptibility to Parkinson's disease.

Authors:  Caroline Williams-Gray; An Goris; Thomas Foltynie; Alastair Compston; Stephen Sawcer; Roger A Barker
Journal:  J Neurol       Date:  2009-02-16       Impact factor: 4.849

5.  Sexual dimorphism in xenobiotic genetic variants-mediated risk for Parkinson's disease.

Authors:  Nadella Kumudini; Addepally Uma; Shaik Mohammad Naushad; Rukmini Mridula; Rupam Borgohain; Vijay Kumar Kutala
Journal:  Neurol Sci       Date:  2014-01-04       Impact factor: 3.307

6.  Manganese activates NLRP3 inflammasome signaling and propagates exosomal release of ASC in microglial cells.

Authors:  Souvarish Sarkar; Dharmin Rokad; Emir Malovic; Jie Luo; Dilshan S Harischandra; Huajun Jin; Vellareddy Anantharam; Xuemei Huang; Mechelle Lewis; Arthi Kanthasamy; Anumantha G Kanthasamy
Journal:  Sci Signal       Date:  2019-01-08       Impact factor: 8.192

7.  In search of the causes of Parkinson's disease, seasons 1 to 4.

Authors:  Alexis Elbaz
Journal:  Eur J Epidemiol       Date:  2011-05-31       Impact factor: 8.082

8.  SLC6A3 is a risk factor for Parkinson's disease: a meta-analysis of sixteen years' studies.

Authors:  Desheng Zhai; Songji Li; Ying Zhao; Zhicheng Lin
Journal:  Neurosci Lett       Date:  2013-11-07       Impact factor: 3.046

9.  Paraoxonase 1, agricultural organophosphate exposure, and Parkinson disease.

Authors:  Angelika D Manthripragada; Sadie Costello; Myles G Cockburn; Jeff M Bronstein; Beate Ritz
Journal:  Epidemiology       Date:  2010-01       Impact factor: 4.822

10.  Spatial distribution of Parkinson's disease mortality in Spain, 1989-1998, as a guide for focused aetiological research or health-care intervention.

Authors:  Jesús de Pedro-Cuesta; Eduard Rodríguez-Farré; Gonzalo Lopez-Abente
Journal:  BMC Public Health       Date:  2009-12-02       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.